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Background
Plasmodium falciparum malaria is a pressing global health problem. A previous study 
of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given 
with an adjuvant system (AS02A), showed a 30% rate of protection against clinical 
malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given 
with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, 
a target population for vaccine licensure.
Methods
We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as com-
pared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The 
primary end point was fever with a falciparum parasitemia density of more than 
2500 parasites per microliter, and the mean duration of follow-up was 7.9 months 
(range, 4.5 to 10.5).
Results
A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine 
or the control (rabies) vaccine. Among the 809 children who completed the study pro-
cedures according to the protocol, the cumulative number in whom clinical malaria 
developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to 
receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% 
confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, 
there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as com-
pared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate 
of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 
children were included in the intention-to-treat analysis, which showed an unad-
justed efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious 
adverse events among recipients of RTS,S/AS01E, and this reduction was not only 
due to a difference in the number of admissions directly attributable to malaria.
Conclusions
RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov 
number, NCT00380393.)
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Worldwide, the mortality and morbidity associated with Plasmodium falciparum malaria are high.1-3 Progress 
has been made in controlling malaria by intro-
ducing insecticide-treated nets4 and highly effec-
tive artemisinin-based combination treatments.5 
There is evidence that the incidence of malaria is 
falling in some areas.6-10 These advances have re-
newed interest in the prospects for the control of 
malaria and even its elimination in areas in which 
P. falciparum was previously endemic.11 A safe and 
affordable vaccine providing protection against 
malaria would be an important addition to con-
trol strategies and should be assessed in the con-
text of the use of insecticide-treated nets and the 
availability of artemisinin-based combination 
treatments.
The candidate pre-erythrocytic malaria vaccine 
RTS,S targets the circumsporozoite protein and 
has been evaluated in combination with two dif-
ferent adjuvant systems: AS01 and AS02. Clinical 
development of RTS,S in field trials began with 
the AS02 adjuvant system. Preliminary estimates 
of rates of efficacy against infection after curative 
antimalarial treatment were 34% (95% confidence 
interval [CI], 8 to 53) in adults12 and 66% (95% 
CI, 43 to 80) in infants.13 The rate of efficacy 
against the more clinically relevant end point of 
clinical malaria in children 1 to 4 years of age 
was 30% (95% CI, 11 to 45).14
Planning is now under way for a multicenter 
phase 3 trial. However, since preliminary data sug-
gested better immunogenicity with the AS01 ad-
juvant,15-17 there was a need to evaluate RTS,S ad-
ministered with the AS01 adjuvant system before 
selecting the vaccine formulation for phase 3. We 
evaluated the efficacy of RTS,S/AS01E against clin-
ical malaria in children 5 to 17 months of age.
Me thods
Study Design
The study was randomized, controlled, and dou-
ble-blind and was prospectively registered at 
ClinicalTrials.gov. Approval was obtained from 
the Kenyan Medical Research Institute National 
Ethics Committee, the Tanzanian Medical Re-
search Coordinating Committee, the Central Ox-
ford Research Ethics Committee, the London 
School of Hygiene and Tropical Medicine Ethics 
Committee, and the Western Institutional Review 
Board in Seattle. An independent data and safety 
monitoring board and local safety monitors were 
appointed. The study was conducted in accordance 
with the Helsinki Declaration of 1964 (revised in 
1996) and according to Good Clinical Practice 
guidelines.
GlaxoSmithKline Biologicals was the study 
sponsor. The database was managed by the spon-
sor and was opened to the principal investigators 
at the time of unblinding. Analysis was per-
formed in parallel by an industry author who is 
an employee of the sponsor and an academic au-
thor. Two academic authors and the industry 
author vouch for the data and analysis. The first 
draft of the manuscript was written by an aca-
demic author, who subsequently implemented re-
visions from all the authors after their review.
GlaxoSmithKline and both study sites (Kilifi, 
Kenya, and Korogwe, Tanzania) received funding 
to undertake the work described in this report 
from the Program for Appropriate Technology in 
Health (PATH) Malaria Vaccine Initiative (MVI), 
which was involved in all aspects of the study 
design. Permission to submit the manuscript for 
publication was given by the directors of the 
Kenya Medical Research Institute and the Nation-
al Institute for Medical Research of Tanzania. 
More details of the investigators’ and sponsor’s 
roles in the study are given in the Supplementary 
Appendix, available with the full text of this article 
at www.nejm.org.
Figure 1 (facing page). Screening, Randomization, 
and Follow-up of Study Participants.
The 177 children who were deemed ineligible at screen-
ing had an age outside the acceptable range (67 children), 
an acute disease at enrollment (23), a serious illness 
on clinical screening (42), a laboratory result outside 
the acceptable limit (28), or another reason for ineligi-
bility: a parent or guardian who was judged by the in-
vestigator to be unable to give consent, an inability to 
follow the protocol, a planned administration of another 
vaccination, or the use of blood products in the previ-
ous 3 months (17). The other reasons for ineligibility 
or withdrawal from the study were enrollment in other 
clinical trials (for the eight children excluded at screen-
ing only), missed vaccinations because of hospital ad-
mission, contraindications to further vaccination, med-
ical conditions not permitted according to the protocol, 
and unavailability of documentation about concomitant 
vaccination.
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894 Underwent randomization
1162 Children were assessed for eligibility
177 Were ineligible
57 Withdrew consent
11 Were lost to follow-up
15 Left study area
8 Had other reason for exclusion
447 Were assigned to receive
RTS,S/AS01E vaccine
447 Were assigned to receive
control (rabies vaccine)
2 Withdrew consent
5 Left study area
1 Had other reason
for withdrawal
1 Withdrew consent
5 Left study area
3 Had other reason
for withdrawal
439 Received second dose 438 Received second dose
447 Received first dose 447 Received first dose
1 Withdrew consent
4 Left study area
1 Withdrew consent
3 Left study area
1 Had other reason
for withdrawal
434 Received third dose 433 Received third dose
3 Were lost to follow-up
4 Were noncompliant
with dosing intervals
12 Had other reason
  for withdrawal
2 Were lost to follow-up
3 Were noncompliant
with dosing intervals
8 Had other reason
for withdrawal
415 Were included in the
according-to-protocol cohort
420 Were included in the
according-to-protocol cohort
13 Had missing covariates13 Had missing covariates
402 Underwent according-to-
protocol analysis
407 Underwent according-to-
protocol analysis
447 Were included
in intention-to-
treat analysis
447 Were included
in intention-to-
treat analysis
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Study Participants
We randomly assigned children to receive either 
the candidate malaria vaccine or a licensed rabies 
vaccine in a 1:1 ratio at the two study sites (for 
more details, see the Supplementary Appendix). 
Vaccinations took place over a 6-month period 
from March through August 2007. Active surveil-
lance for malaria began 2.5 months after the first 
vaccination and continued throughout the follow-
up period. Venous-blood samples were taken to 
screen for eligibility, 3 months after the first vac-
cination as well as in March 2008 (irrespective of 
the time of recruitment). The study was unblind-
ed at the time of the final blood test, in March 
2008. Hence, the duration of follow-up varied ac-
cording to the time of recruitment, between 4.5 
and 10.5 months (mean, 7.9). A locked database 
containing data collected through the time of the 
final blood test was unblinded and the data were 
analyzed in August 2008. The database of adverse 
events collected up to August 4, 2008, was locked, 
and the data were analyzed in August 2008.
The participating children were 5 to 17 months 
of age at the time of the first vaccination, were 
healthy, and were residents of the study area. De-
tails of the screening are given in the Supplemen-
tary Appendix. Written informed consent in an 
appropriate language (Swahili, Chonyi, or Giria-
ma) was obtained from each child’s parent (or 
parents) or guardian before the study procedures 
were initiated. Nonliterate parents indicated con-
sent using a thumbprint, and a signature was 
obtained from a literate witness.
Vaccines
Children were randomly assigned to receive three 
doses of RTS,S/AS01E or three doses of a human 
diploid-cell rabies vaccine (rabies vaccine BP, Sanofi-
Pasteur). Both vaccines were administered intra-
muscularly in the deltoid, with one dose given 
each month for 3 months. Further details about 
the vaccines are given in the Supplementary Ap-
pendix.
Randomization and Vaccination
The RTS,S/AS01E and rabies vaccines were pack-
aged in identical boxes labeled with treatment 
numbers from a randomization list generated at 
GlaxoSmithKline Biologicals in Rixensart, Bel-
gium, and then shipped to the trial sites. Block 
randomization was used, with stratification ac-
cording to study site. Subjects were assigned treat-
ment numbers on the basis of order of attendance 
at the clinic. Boxes containing the assigned vac-
cine were opened out of sight of the investigators 
who evaluated the study end points, the study 
subjects, and their parents or guardians. The sy-
ringe used to draw up the vaccine was masked. 
Personnel preparing the vaccines were aware of 
the treatment assignments but took no other part 
in study-related procedures and were instructed 
not to reveal the assignments to either the parents 
or guardians of the study subjects or the investi-
gators.
Monitoring for Episodes of Clinical Malaria
The primary end point was a clinical episode of 
malaria, defined as an axillary temperature of 
37.5°C or higher with a P. falciparum density of more 
than 2500 parasites per microliter. The presence 
of any falciparum parasitemia density with a tem-
perature of 37.5°C or higher was a secondary end 
point.
Active surveillance was performed through 
weekly visits by field-workers to the home to 
identify febrile children. Passive surveillance was 
performed by field-workers and by personnel in 
the local health facilities. Further details of these 
visits, as well as safety assessments and labora-
tory methods, are described in the Supplemen-
tary Appendix. The implementation of active sur-
veillance was unintentionally delayed by 3 months 
in Korogwe, but passive surveillance was conduct-
ed during this period.
Statistical Analysis
The study was designed to have a statistical power 
of 90% to detect a 30% efficacy rate, at a signifi-
cance level of 0.05, based on a projected malaria 
incidence of 36% among children receiving the 
rabies-vaccine doses during a 4-month surveil-
lance period. This design required 800 subjects 
who could be evaluated, with a total enrollment 
of 890 subjects to allow for loss to follow-up. 
Before the beginning of the study, it was planned 
that the number of episodes of clinical malaria 
would be monitored in real time and that un-
blinding of the data would be delayed if fewer 
than 245 episodes had been recorded by the time 
this number was reached. In fact, the rates of 
malaria were considerably lower than expected. 
The unblinding was delayed, but by the time the 
transmission season was ending, just over 100 
episodes had been recorded. We believed that the 
target of 245 episodes would not be reached in 
the near future, and the trial was therefore un-
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blinded on August 4, 2008, after discussion among 
the investigators, sponsors, regulatory authorities, 
and data and safety monitoring board.
An analysis plan was agreed on by the data 
and safety monitoring board, sponsor, and inves-
tigators before the unblinding. The primary analy-
sis was an estimate of the hazard ratio for the 
first or only episode of malaria involving fever 
and a parasite density above 2500 per microliter 
(the primary end point) for the group that re-
ceived the RTS,S/AS01E vaccine as compared with 
the control group in the according-to-protocol 
cohort. Secondary analyses included episodes of 
malaria involving any parasitemia density with 
fever (a secondary end point) in the according-
to-protocol cohort, as well as cases qualifying as 
primary and secondary end points in the inten-
tion-to-treat cohort (i.e., all children randomly 
assigned to receive vaccinations) and multiple epi-
sodes of malaria (analyzed by means of Poisson 
regression). The period for the according-to-
protocol analysis was 2 weeks after the last vac-
cination until the final blood test. The period for 
the intention-to-treat analysis was the time from 
the first vaccination until the final blood test. 
More details are given in the Supplementary Ap-
pendix.
The effect of anticircumsporozoite antibodies 
on the risk of clinical malaria was examined with 
the use of titers measured 1 month after the 
third dose. Log-transformed titers (with undetect-
able levels scored as a value that was half the 
lower limit of detection) were used as a continu-
ous variable in an adjusted Cox regression analy-
sis for the children receiving the RTS,S/AS01E 
vaccine.
Safety data are presented for the intention-to-
treat cohort, and efficacy data are presented for 
both the according-to-protocol cohort and the 
intention-to-treat cohort. Data were analyzed from 
the time of the first vaccination until the time of 
the final blood test for efficacy, but all the avail-
able safety data up to August 4, 2008 (the time 
of unblinding), were analyzed. Serious adverse 
events are described with the use of the pre-
ferred terms from the Medical Dictionary for 
Regulatory Activities (MedDRA).18
R esult s
A total of 1162 children were screened; 894 were 
randomly assigned to a study group and received 
at least one vaccination, and data for 809 were 
included in the according-to-protocol analysis of 
efficacy (Fig. 1). The demographic characteristics 
of the participants were balanced between the 
two vaccine groups (Table 1).
Efficacy
In the according-to-protocol analysis (of data 
over a mean of 8 months of follow-up, beginning 
2 weeks after the final vaccination), the cumula-
tive incidence of the first or only malarial epi-
sode, as defined for the primary end point, was 
8% (32 of 402 subjects) in the group that received 
the RTS,S/AS01E vaccine, as compared with 16% 
(66 of 407 subjects) in the group that received the 
rabies vaccine. Cox regression provided an adjust-
ed efficacy of 53% (95% CI, 28 to 69; P<0.001) 
Table 1. Baseline Characteristics of the Subjects, According to Vaccine Group.
Characteristic
RTS,S/AS01E 
(N = 447)
Rabies 
(N = 447)
Mean age — mo 11.4 11.3
Sex — no. (%)
Female 230 (51) 222 (50)
Male 217 (49) 225 (50)
Site  — no. (%)
Kilifi, Kenya 223 (50) 224 (50)
Korogwe, Tanzania 224 (50) 223 (50)
Geographic cluster — no. (%)
Kilifi, Kenya
Junju West 63 (14) 48 (11)
Junju East 52 (12) 58 (13)
Pingilikani South 54 (12) 60 (13)
Pingilikani North 54 (12) 58 (13)
Korogwe, Tanzania
Ngombezi 41 (9) 39 (9)
Makuyuni 152 (34) 150 (34)
Mbagai 31 (7) 34 (8)
Distance to dispensary — no. (%)
<5 km 299 (67) 290 (65)
5–10 km 122 (27) 131 (29)
>10 km 26 (6) 26 (6)
Bed net — no. (%)
None 80 (18) 95 (21)
Treated, with no holes 103 (23) 99 (22)
Treated, with holes 85 (19) 69 (15)
Untreated, with no holes 57 (13) 54 (12)
Untreated, with holes 95 (21) 108 (24)
Missing data 27 (6) 22 (5)
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and an unadjusted efficacy of 55% (95% CI, 31 to 
70; P<0.001) (Fig. 2).
In the intention-to-treat analysis (of data col-
lected over a mean of 10.5 months of follow-up, 
beginning with the first vaccination), the cumu-
lative incidence of the first or only episode meet-
ing the criteria for the primary end point was 
9% (42 of 447 subjects) in the group receiving the 
RTS,S/AS01E vaccine and 17% (78 of 447) in the 
group receiving the rabies vaccine, with an un-
adjusted efficacy rate of 49% (95% CI, 26 to 65; 
P<0.001) on the basis of Cox regression.
In the according-to-protocol analysis, 6 of 402 
subjects in the RTS,S/AS01E group (1%) and 14 
of 407 subjects in the rabies-vaccine group (3%) 
had more than one episode of clinical malaria. 
In the intention-to-treat analysis, 6 of the 447 
subjects in the RTS,S/AS01E group (1%) and 17 
of 447 in the rabies-vaccine group (4%) had more 
than one clinical episode. The rate of efficacy 
against all clinical episodes meeting the criteria 
for the primary end point was 56% (95% CI, 31 to 
72; P<0.001) for the RTS,S/AS01E vaccine on the 
basis of Poisson regression, which was similar to 
the rate of efficacy against first or only episodes. 
The results of the intention-to-treat analysis were 
similar (Table 2).
Estimates of efficacy according to the second-
ary end point of fever with any P. falciparum para-
sitemia density were similar to those according 
to the primary end point (Table 2). Two cases of 
parasitemia were identified in the rabies-vaccine 
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Figure 2. Kaplan–Meier Estimates of the Time to the First or Only Episode of Clinical Malaria. 
Clinical malaria was defined as fever with a parasite count of more than 2500 per microliter. Panel A shows data for 
the according-to-protocol analysis, beginning 2 weeks after the last vaccination; Panel B shows data for the intention-to-
treat analysis, beginning at the time of the first vaccination. P values were calculated with the use of the log-rank test.
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group when clinicians, responding to the con-
cerns of the parents, believed a malaria test was 
warranted despite the absence of fever. Including 
these two cases did not change the results ap-
preciably. Estimates of efficacy were similar at 
each site (in Kilifi, 55%; 95% CI, 25 to 73; P = 0.002; 
and in Korogwe, 56%; 95% CI, 4 to 80; P = 0.04).
Asymptomatic parasitemia was detected infre-
quently at the time of the final blood test (in 2% 
of subjects in the RTS,S/AS01E group and 3% of 
those in the rabies-vaccine group), and the mean 
hemoglobin level was similar in the two vaccine 
groups (10.3 g per deciliter and 10.4 g per deci-
liter, respectively; P = 0.22).
Safety
In all, 47 of the 447 children receiving the RTS,S/
AS01E vaccine had one or more serious adverse 
events (11%; 95% CI, 8 to 14), as did 82 of the 447 
children receiving the rabies vaccine (18%; 95% 
CI, 15 to 22). The lower rate of serious adverse 
events in the RTS,S/AS01E group was only partly 
accounted for by a reduction in admissions relat-
ed to falciparum malaria. A total of 51 MedDRA-
preferred terms were used to describe the serious 
adverse events. The numbers of children with the 
three most common diagnoses and those with 
serious adverse events not related to malaria are 
shown according to vaccine group in Table 3. 
Less-common serious adverse events (those oc-
curring fewer than 10 times per group) are not 
shown, but there was no obvious imbalance be-
tween the two groups in the rates of these events. 
Laboratory safety tests did not reveal any signifi-
cant difference in the frequency of out-of-range 
values between the two treatment groups. No 
Table 3. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Intention-to-Treat Cohort, According to the Vaccine Group.*
Events RTS,S/AS01E Rabies
No. of Subjects 
or Doses Percent (95% CI)
No. of Subjects 
or Doses Percent (95% CI)
SAEs, per-subject analysis N = 447 N = 447
Any 47 11 (8–14) 82 18 (15–22)
In absence of Plasmodium falciparum infection 41 9 (8–14) 61 14 (11–17)
Pneumonia 18 4 (2–6) 26 6 (4–8)
Gastroenteritis 10 2 (1–4) 21 5 (3–7)
P. falciparum infection 7 2 (1–3) 21 5 (3–7)
Death 1 <1 (0–1) 1 <1 (0–1)
Related to vaccination 1 <1 (0–1) 0 0 (0–1)
Unsolicited AE, per-subject analysis N = 447 N = 447
Any 349 78 (74–82) 332 74 (70–78)
Gastroenteritis 103 23 (19–27) 83 19 (15–23)
Pneumonia 152 34 (30–39) 143 32 (28–37)
Upper respiratory tract infection 81 18 (15–22) 57 13 (10–16)
Impetigo 27 6 (4–9) 20 5 (3–7)
Lower respiratory tract infection 27 6 (4–9) 28 6 (4–9)
Rhinitis 27 6 (4–9) 19 4 (3–7)
Severity grade 3 36 8 (6–11) 51 11 (9–15)
Solicited local AEs, per-dose analysis N = 1320 N = 1320
Pain
Any 172 13 (11–15) 157 12 (10–14)
Severity grade 3 0 0 (0–0) 0 0 (0–0)
Swelling
Any 34 3 (2–4) 16 1 (1–2)
Severity grade 3 3 <1 (0–1) 0 0 (0–0)
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out-of-range values were considered to be related 
to vaccination.
Between the time of the first vaccination 
and the time of unblinding, one episode in the 
RTS,S/AS01E group met the criteria for severe 
malaria, as compared with eight episodes of 
severe malaria among seven children in the rabies-
vaccine group. Of the children with severe ma-
laria, two had cerebral malaria, one had severe 
anemia, and the remaining five had other types 
of severe malaria (defined in the Supplementary 
Appendix). All children treated for acute malar-
ial infection recovered without sequelae.
One serious adverse event was judged to be 
related to vaccine: a simple febrile seizure, ob-
served 1 day after vaccination with RTS,S/AS01E. 
The seizure terminated spontaneously, and there 
were no neurologic abnormalities detected 24 
hours afterward. Despite the facilitated access to 
medical care during the study, two children died 
(one at home and one while being brought to the 
dispensary), with no clinical evaluation. One 
child, who had been vaccinated 9 months earlier 
with RTS,S/AS01E, had generalized convulsions 
and loss of consciousness. Traditional medicine 
was used, but the child died without being 
brought to the health center. The other child, 
who had been given the rabies vaccine and was 
subsequently withdrawn from the study because 
of the parents’ anxiety about the blood sampling, 
had atypical prolonged seizures, lost conscious-
ness, and died while being brought to the health 
center. Neither death was judged to be related to 
the study vaccine.
The frequency of local adverse events during 
the first 7 days after each of the three vaccina-
Table 3. (Continued.)
Events RTS,S/AS01E Rabies
No. of Subjects  
or Doses Percent (95% CI)
No. of Subjects  
or Doses Percent (95% CI)
Solicited systemic AEs, per-dose analysis N = 1320 N = 1318
Drowsiness
Any 81 6 (5–8) 64 5 (4–6)
Severity grade 3 0 0 (0–0) 1 <1 (0–0)
Related to vaccination 69 5 (4–7) 60 5 (4–6)
Irritability
Any 59 5 (3–6) 21 2 (1–2)
Severity grade 3 0 0 (0–0) 0 0 (0–0)
Related to vaccination 44 3 (2–4) 16 1 (1–2)
Loss of appetite
Any 64 5 (4–6) 43 3 (2–4)
Severity grade 3 0 0 (0–0) 2 <1 (0–1)
Related to vaccination 29 2 (2–3) 16 1 (1–2)
Fever†
Any 149 11 (10–13) 409 31 (29–34)
Severity grade 3 5 <1 (0–1) 12 1 (1–2)
Related to vaccination 132 10 (8–12) 396 30 (28–33)
* The three most common severe adverse events (SAEs) are listed individually, as are unsolicited adverse events (AEs) (those reported by par-
ents spontaneously rather than in response to questions from field-workers) occurring in more than 5% of children in each group. SAEs are re-
ported for the period from the first dose of vaccine until the unblinding of the database on August 4, 2008. Unsolicited AEs were recorded dur-
ing the first 30 days (including the day of vaccination). Local AEs and solicited systemic AEs are reported for the first 7 days (including the 
day of vaccination) after each of the three vaccinations. Data on events reported per vaccine dose were available for the 447 subjects receiv-
ing the first dose in each group, for the 439 subjects in the RTS,S/AS01E group and the 438 in the rabies-vaccine group who received the 
second dose, and for the 434 subjects in the RTS,S/AS01E group and the 433 in the rabies-vaccine group who  received the third dose — for 
a total of 1320 and 1318 doses in the respective groups.
† Fever was defined as an axillary temperature of 37.5°C or greater.
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tions is shown in Table 3. Unsolicited adverse 
events (those reported by parents spontaneously 
rather than in response to questions from field-
workers) occurring in more than 5% of children 
per group are also shown. Unsolicited symptoms 
were recorded during the first 30 days. These 
were classified according to the MedDRA-pre-
ferred term, and 105 preferred terms were as-
signed. There was no obvious imbalance between 
the two vaccine groups with respect to these 
other, less-frequent adverse events, and all were 
expected events for the population. A total of 
77% of children in the RTS,S/AS01E group and 
76% of those in the rabies-vaccine group had un-
solicited adverse events that were not related to 
malaria.
Immunogenicity
The geometric mean titer of anticircumsporo-
zoite antibody 1 month after the third vaccina-
tion was 539.6 enzyme-linked immunosorbent 
assay units (EU) per milliliter (95% CI, 500.7 to 
581.6) in the RTS,S/AS01E group, as compared 
with 0.3 EU per milliliter (95% CI, 0.3 to 0.3) in 
the rabies-vaccine group (with a limit of detection 
of 0.5 EU per milliliter). The geometric mean titer 
in the RTS,S/AS01E group had fallen by the time 
of the final cross-sectional survey at 4.5 to 10.5 
months (71.9 EU per milliliter; 95% CI, 66 to 79) 
but remained higher than in the rabies-vaccine 
group (0.3 EU per milliliter; 95% CI, 0.2 to 0.3).
There was a wide range of antibody titers after 
vaccination (Fig. 3), but more than 99% of the 
children in the RTS,S/AS01E group had detect-
able anticircumsporozoite titers. There was no 
evidence that RTS,S/AS01E-vaccinated children 
with high titers had greater protection against 
clinical disease than those with lower titers. Each 
increase by a factor of 10 in the anticircum-
sporozoite antibody titer (assessed 1 month after 
the third dose) was associated with an increase in 
efficacy of 9% (95% CI, −25 to 34; P = 0.58).
All children had received the usual course of 
hepatitis B vaccine, with doses at 6, 10, and 14 
weeks of age; the prevalence of hepatitis B virus 
surface antibody titers above 10 mIU per millili-
ter was 97% at screening and 100% one month 
after the third RTS,S/AS01E vaccination. There 
was no correlation between the hepatitis B virus 
surface antibody titer at screening and the cir-
cumsporozoite titer after vaccination (r = 0.06, 
P = 0.21), but there was a strong correlation be-
tween the hepatitis B virus surface antibody 
titer at screening and the titer after vaccination 
(r = 0.48, P<0.001).
Discussion
The RTS,S/AS01E malaria vaccine has significant 
efficacy against clinical malaria in the field in a 
target group for licensure (i.e., children 5 to 17 
months of age). Our estimate of efficacy against 
clinical malaria for RTS,S given with the AS01 
adjuvant system is higher than previous estimates 
with the use of the AS02 adjuvant system.14 AS01 
is a more immunogenic adjuvant than AS02 in 
comparative studies.15-17 The mean antibody titer 
in our study (539.6 EU per milliliter; 95% CI, 
500.7 to 581.6) was higher than the antibody ti-
ters induced by RTS,S/AS02D in young infants 
(199.9 EU per milliliter; 95% CI, 150.9 to 264.7)13 
and in children 1 to 4 years of age (158 EU per 
milliliter; 95% CI, 142 to 176).14 The antibody 
titer was 40 EU per milliliter (95% CI, 36 to 45) 
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Figure 3. Time Course of Anticircumsporozoite Antibody Titers 
for the According-to-Protocol Cohort, According to Vaccination Group.
The box-and-whisker plots show the distribution of anticircumsporozoite 
antibodies according to time point and according to vaccination group. 
When only a horizontal line is shown, it represents the 25th, 50th, and 75th 
percentiles (all of which were identical). Otherwise, the horizontal line within 
each box represents the median, the top and bottom of each box represent 
the 25th and 75th percentiles, respectively, and the I bars represent the high-
est and lowest values within 1.5 times the interquartile range. The circles 
denote outliers. EU denotes enzyme-linked immunosorbent assay units.
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6 months after vaccination with RTS,S/AS02D, but 
in our study, the titer was 71.9 EU per milliliter 
(95% CI, 65.7 to 78.6) 4.5 to 10.5 months (mean, 
8) after vaccination with RTS,S/AS01E.
However, there are other differences between 
the studies. The intensity of malaria transmission 
is falling on the East African coast, probably as a 
result of increasing use of insecticide-treated 
nets.6,7 We used active and passive case detection 
rather than passive case detection alone and stud-
ied a younger group of children than those in 
Mozambique.14 In Mozambique, there was 47% 
efficacy against clinical malaria among children 
under 2 years of age, as compared with 30% 
overall efficacy among children 1 to 4 years of 
age, albeit with wide confidence intervals (15 to 
67%) and without a significant interaction be-
tween age and vaccine efficacy. Whatever the 
explanation for the higher efficacy and immuno-
genicity, our data support the conduct of a phase 
3 trial of RTS,S/AS01E.
We detected fewer serious adverse events in 
children receiving the RTS,S/AS01E vaccine than 
in children receiving the rabies vaccine. Although 
previous studies have shown a reduced rate of 
serious adverse events in children vaccinated with 
RTS,S/AS02A,19 our results suggest that not all 
of this reduction is directly attributable to ma-
laria. This raises the possibility that preventing 
malaria through vaccination may have indirect 
as well as direct effects. Some trials have sug-
gested indirect effects of the use of insecticide-
treated nets,20 but this has not been confirmed 
in other studies.21 Indirect effects of malaria 
might be more likely to result from chronic para-
sitemia than from the acute, promptly treated 
episodes seen in our cohort,22 although a de-
creased rate of growth in children after an acute 
episode has also been observed.23 The possible 
indirect benefits of vaccination will be examined 
further in a phase 3 multicenter trial.
The immunologic correlate of protection re-
mains unknown. Antibodies13 and cell-mediated 
immunity24,25 have been associated with protec-
tion against infection, but not against clinical 
disease,14 in previous studies. We found no cor-
relation between the anticircumsporozoite anti-
body titer and protection against clinical disease 
in this study, despite the wide variation in anti-
circumsporozoite antibody responses among the 
vaccinated children. This result does not rule out 
a role for anticircumsporozoite antibody respons-
es. For instance, in studies of immunity to blood-
stage parasites, the functional properties of anti-
bodies, but not the overall titer, determine the 
outcome.26 Studies of cell-mediated immunity in 
this cohort are still under way.
There was a 3-month delay in implementing 
active case detection at one site in our study, ac-
counting for 87 person-years at risk out of a total 
of 491 person-years at risk for the two sites. Dur-
ing this period, passive case detection was im-
plemented, and transmission appeared to be low 
(with identification of <25% of the total cases). 
Furthermore, during the rest of the study, 92% 
of malarial episodes were detected through pas-
sive rather than active case detection, and esti-
mates of efficacy were similar at the two sites. 
Hence, it seems unlikely that a large number of 
cases were missed. Our findings indicate that the 
RTS,S/AS01E vaccine should be further tested in a 
phase 3, multicenter trial.
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clinical trial registration
The Journal requires investigators to register their clinical trials 
in a public trials registry. The members of the International Committee  
of Medical Journal Editors (ICMJE) will consider most clinical trials for publication 
only if they have been registered (see N Engl J Med 2004;351:1250-1).  
Current information on requirements and appropriate registries  
is available at www.icmje.org/faq.pdf.
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